|
NL154600B
(nl)
|
1971-02-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
|
|
NL154598B
(nl)
|
1970-11-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
|
|
NL154599B
(nl)
|
1970-12-28 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
|
|
US3901654A
(en)
|
1971-06-21 |
1975-08-26 |
Biological Developments |
Receptor assays of biologically active compounds employing biologically specific receptors
|
|
US3853987A
(en)
|
1971-09-01 |
1974-12-10 |
W Dreyer |
Immunological reagent and radioimmuno assay
|
|
US3867517A
(en)
|
1971-12-21 |
1975-02-18 |
Abbott Lab |
Direct radioimmunoassay for antigens and their antibodies
|
|
NL171930C
(nl)
|
1972-05-11 |
1983-06-01 |
Akzo Nv |
Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
|
|
US3850578A
(en)
|
1973-03-12 |
1974-11-26 |
H Mcconnell |
Process for assaying for biologically active molecules
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US3935074A
(en)
|
1973-12-17 |
1976-01-27 |
Syva Company |
Antibody steric hindrance immunoassay with two antibodies
|
|
US3996345A
(en)
|
1974-08-12 |
1976-12-07 |
Syva Company |
Fluorescence quenching with immunological pairs in immunoassays
|
|
US4034074A
(en)
|
1974-09-19 |
1977-07-05 |
The Board Of Trustees Of Leland Stanford Junior University |
Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
|
|
US3984533A
(en)
|
1975-11-13 |
1976-10-05 |
General Electric Company |
Electrophoretic method of detecting antigen-antibody reaction
|
|
US4036945A
(en)
|
1976-05-03 |
1977-07-19 |
The Massachusetts General Hospital |
Composition and method for determining the size and location of myocardial infarcts
|
|
US4098876A
(en)
|
1976-10-26 |
1978-07-04 |
Corning Glass Works |
Reverse sandwich immunoassay
|
|
JPS552602A
(en)
|
1978-06-20 |
1980-01-10 |
Yamasa Shoyu Co Ltd |
1-beta-d-arabinofranosylcytosine-5'-phosphoric acid oleyl ester
|
|
US5206018A
(en)
|
1978-11-03 |
1993-04-27 |
Ayerst, Mckenna & Harrison, Inc. |
Use of rapamycin in treatment of tumors
|
|
US4342828A
(en)
|
1979-07-20 |
1982-08-03 |
Morinaga Milk Industry Co., Ltd. |
Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
|
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4879219A
(en)
|
1980-09-19 |
1989-11-07 |
General Hospital Corporation |
Immunoassay utilizing monoclonal high affinity IgM antibodies
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5011771A
(en)
|
1984-04-12 |
1991-04-30 |
The General Hospital Corporation |
Multiepitopic immunometric assay
|
|
JPS61227526A
(ja)
|
1984-07-25 |
1986-10-09 |
Chugai Pharmaceut Co Ltd |
新規なコロニー刺激因子
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
EP0215126B1
(en)
|
1985-02-08 |
1991-07-31 |
Chugai Seiyaku Kabushiki Kaisha |
Human granulocyte colony stimulating factor
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
EP1186663A1
(en)
|
1985-08-23 |
2002-03-13 |
Kirin-Amgen, Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
DE3681551D1
(de)
|
1985-09-30 |
1991-10-24 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granulozyten-colony stimulierender faktor.
|
|
JPH0618778B2
(ja)
|
1985-10-04 |
1994-03-16 |
中外製薬株式会社 |
白血球減少症治療剤
|
|
ATE74272T1
(de)
|
1986-01-22 |
1992-04-15 |
Chugai Pharmaceutical Co Ltd |
Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
|
|
EP0230980B2
(en)
|
1986-01-22 |
1996-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical agent for promoting the recovery of hemopoietic capacity
|
|
DK203187A
(da)
|
1986-04-22 |
1987-10-23 |
Immunex Corp |
Human g-csf proteinekspression
|
|
GR871067B
(en)
|
1986-07-18 |
1987-11-19 |
Chugai Pharmaceutical Co Ltd |
Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JPH0725689B2
(ja)
|
1986-10-07 |
1995-03-22 |
中外製薬株式会社 |
顆粒球コロニ−刺激因子を含有する徐放性製剤
|
|
JP2618618B2
(ja)
|
1988-03-04 |
1997-06-11 |
協和醗酵工業株式会社 |
抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
|
|
DK174044B1
(da)
|
1986-12-23 |
2002-05-06 |
Kyowa Hakko Kogyo Kk |
Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
|
|
CA1340810C
(en)
|
1988-03-31 |
1999-11-02 |
Motoo Yamasaki |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
|
ES2063783T3
(es)
|
1988-06-03 |
1995-01-16 |
Chugai Pharmaceutical Co Ltd |
Factor de cristalino humano de estimulacion de colonias de granulocitos y procedimiento para su preparacion.
|
|
US5202117A
(en)
|
1988-08-24 |
1993-04-13 |
Koichiro Tsuji |
Method of treating thrombi with g-csf
|
|
US5218092A
(en)
|
1988-09-29 |
1993-06-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US5104651A
(en)
|
1988-12-16 |
1992-04-14 |
Amgen Inc. |
Stabilized hydrophobic protein formulations of g-csf
|
|
DE68925966T2
(de)
|
1988-12-22 |
1996-08-29 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
IL96477A0
(en)
|
1989-12-01 |
1991-08-16 |
Amgen Inc |
Megakaryocyte production
|
|
GB9107846D0
(en)
|
1990-04-30 |
1991-05-29 |
Ici Plc |
Polypeptides
|
|
EP0459516A1
(en)
|
1990-06-01 |
1991-12-04 |
Kirin-Amgen, Inc. |
Oral dosage form of biologically active proteins
|
|
JP3249147B2
(ja)
|
1990-06-01 |
2002-01-21 |
キリン−アムジエン・インコーポレーテツド |
生理活性蛋白含有経口製剤
|
|
IE912365A1
(en)
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
|
US5342774A
(en)
|
1991-05-23 |
1994-08-30 |
Ludwig Institute For Cancer Research |
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
|
|
US5541104A
(en)
|
1991-05-23 |
1996-07-30 |
Ludwig Institute For Cancer Research |
Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5250732A
(en)
|
1991-07-18 |
1993-10-05 |
Genentech, Inc. |
Ketamine analogues for treatment of thrombocytopenia
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
DK0822199T3
(da)
|
1991-10-25 |
2004-12-27 |
Amgen Inc |
N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
|
|
US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
FR2686900B1
(fr)
|
1992-01-31 |
1995-07-21 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5281521A
(en)
|
1992-07-20 |
1994-01-25 |
The Trustees Of The University Of Pennsylvania |
Modified avidin-biotin technique
|
|
US6222012B1
(en)
|
1992-08-31 |
2001-04-24 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides presented by HLA molecules, and uses thereof
|
|
PT658113E
(pt)
|
1992-08-31 |
2005-03-31 |
Ludwig Inst Cancer Res |
Nonapeptideo isolado derivado do gene mage-3 e apresentado por hla-a1, e utilizacoes deste
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
EP0711345A1
(en)
|
1993-07-26 |
1996-05-15 |
Dana Farber Cancer Institute |
B7-2: ctl a4/cd 28 counter receptor
|
|
RU2136696C1
(ru)
|
1993-10-14 |
1999-09-10 |
Сейкагаку Корпорейшн |
Новый полипептид и фармацевтическая композиция против вич-инфекции
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
|
KR100316209B1
(ko)
|
1994-03-01 |
2002-06-26 |
에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 |
Mage유전자발현에의한암상태의결정
|
|
US5492126A
(en)
|
1994-05-02 |
1996-02-20 |
Focal Surgery |
Probe for medical imaging and therapy using ultrasound
|
|
USRE38313E1
(en)
|
1994-05-06 |
2003-11-11 |
Institut Gustave Roussy |
Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies
|
|
DK0812206T3
(da)
|
1995-03-01 |
2002-09-09 |
Immunex Corp |
Fremgangsmåde til stimulering af en immunrespons
|
|
DK0766745T3
(da)
|
1995-04-08 |
2002-11-25 |
Lg Chemical Ltd |
Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
|
WO1998016249A1
(en)
|
1996-10-11 |
1998-04-23 |
Bristol-Myers Squibb Company |
Methods and compositions for immunomodulation
|
|
ATE320488T1
(de)
|
1996-11-28 |
2006-04-15 |
Roussy Inst Gustave |
Mutanten des lag-3 proteins, ihre expression und verwendung
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
EA002819B1
(ru)
|
1997-05-14 |
2002-10-31 |
Авентис Фармасьютикалз Продактс Инк. |
Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция
|
|
CA2288964A1
(en)
|
1997-05-21 |
1998-11-26 |
Genentech, Inc. |
Novel administration of thrombopoietin
|
|
WO1998052465A1
(en)
|
1997-05-23 |
1998-11-26 |
Transurgical, Inc. |
Mri-guided therapeutic unit and methods
|
|
US6774279B2
(en)
|
1997-05-30 |
2004-08-10 |
Carnegie Institution Of Washington |
Use of FLP recombinase in mice
|
|
EP0893507A1
(en)
|
1997-07-25 |
1999-01-27 |
Institut Gustave Roussy |
Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
|
|
US6291430B1
(en)
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
|
US6569418B1
(en)
|
1997-12-11 |
2003-05-27 |
University Of Maryland Biotechnology Institute |
Immuno-modulating effects of chemokines in DNA vaccination
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
|
WO2000009152A1
(en)
|
1998-08-14 |
2000-02-24 |
The University Of British Columbia |
Therapeutic chemokine receptor antagonists
|
|
AU762472B2
(en)
|
1998-03-13 |
2003-06-26 |
University Of British Columbia, The |
Therapeutic chemokine receptor antagonists
|
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
|
WO2000006086A2
(en)
|
1998-07-31 |
2000-02-10 |
The Trustees Of Columbia University In The City Of New York |
Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
|
|
US6294459B1
(en)
|
1998-09-03 |
2001-09-25 |
Micron Technology, Inc. |
Anti-reflective coatings and methods for forming and using same
|
|
WO2000020027A2
(en)
|
1998-10-05 |
2000-04-13 |
M & E Biotech A/S |
Methods for therapeutic vaccination
|
|
EP1124614A1
(de)
|
1998-10-27 |
2001-08-22 |
Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. |
Verfahren und vorrichtung zur regelung einer gezielten wärmedeponierung in ein material
|
|
US20060079492A1
(en)
|
1999-10-25 |
2006-04-13 |
Ahlem Clarence N |
Compositions and treatment methods
|
|
SG143018A1
(en)
|
1998-12-23 |
2008-06-27 |
Pfizer |
Human monoclonal antibodies to ctla-4
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
|
SK13822001A3
(sk)
|
1999-03-29 |
2002-02-05 |
Shire Biochem Inc. |
Použitie zlúčenín podľa vynálezu na prípravu farmaceutických prostriedkov na liečenie leukémie
|
|
WO2000066764A1
(en)
|
1999-05-03 |
2000-11-09 |
Ludwig Institute For Cancer Research |
Methods for increasing t cell proliferation
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
AU7072700A
(en)
|
1999-08-23 |
2001-03-19 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
KR20020047132A
(ko)
|
1999-08-24 |
2002-06-21 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
WO2001016180A2
(en)
|
1999-08-27 |
2001-03-08 |
Board Of Regents, The University Of Texas System |
Cd40 agonist compositions and methods of use
|
|
EP2275447A1
(en)
|
1999-11-24 |
2011-01-19 |
Schering Corporation |
Methods of inhibiting metastasis
|
|
GB9927757D0
(en)
|
1999-11-25 |
2000-01-26 |
Kennedy Rheumatology Inst |
Treatment of autoimmune diseases
|
|
ES2629683T3
(es)
|
1999-11-30 |
2017-08-14 |
Mayo Foundation For Medical Education And Research |
B7-H1, una nueva molécula inmunorreguladora
|
|
AU2001233027A1
(en)
|
2000-01-27 |
2001-08-07 |
Genetics Institute, Llc |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
|
WO2001056603A1
(en)
|
2000-02-01 |
2001-08-09 |
Tanox, Inc. |
Cd40-binding apc-activating molecules
|
|
WO2001064716A1
(fr)
|
2000-03-03 |
2001-09-07 |
Nobutaka Fujii |
Composes antiviraux
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
AU5811001A
(en)
|
2000-05-09 |
2001-11-20 |
Univ British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
EP1297135B1
(en)
|
2000-06-28 |
2013-01-09 |
Genetics Institute, LLC |
Pd-l2 molecules: novel pd-1 ligands and uses therefor
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
CA2421183C
(en)
|
2000-09-05 |
2015-06-16 |
Seikagaku Corporation |
Novel polypeptide and anti-hiv agent containing the same
|
|
US8435939B2
(en)
|
2000-09-05 |
2013-05-07 |
Biokine Therapeutics Ltd. |
Polypeptide anti-HIV agent containing the same
|
|
ES2372522T3
(es)
|
2000-09-20 |
2012-01-23 |
Amgen Inc. |
Moléculas de tipo b7 y usos de las mismas.
|
|
US6469543B1
(en)
|
2000-11-09 |
2002-10-22 |
Honeywell International Inc. |
High speed output buffers using voltage followers
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US7630750B2
(en)
|
2001-02-05 |
2009-12-08 |
The Research Foundation For The State University Of New York |
Computer aided treatment planning
|
|
JP3374917B2
(ja)
|
2001-02-16 |
2003-02-10 |
サンケン電気株式会社 |
スイッチング電源装置
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
AU2002338272B2
(en)
|
2001-04-02 |
2007-10-11 |
Dana-Farber Cancer Institute, Inc. |
PD-1, a receptor for B7-4, and uses therefor
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
US8709412B2
(en)
|
2001-06-29 |
2014-04-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of TIM receptor activity in combination with cytoreductive therapy
|
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
ATE519779T1
(de)
|
2001-09-19 |
2011-08-15 |
Roussy Inst Gustave |
An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US20030221931A1
(en)
|
2002-02-28 |
2003-12-04 |
Steve Marsh |
Sliding device
|
|
EP2368982A3
(en)
|
2002-03-21 |
2011-10-12 |
Sangamo BioSciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US8774913B2
(en)
|
2002-04-08 |
2014-07-08 |
Medtronic Ardian Luxembourg S.A.R.L. |
Methods and apparatus for intravasculary-induced neuromodulation
|
|
US20030223989A1
(en)
|
2002-04-18 |
2003-12-04 |
Pluenneke John D. |
CD137 agonists to treat patients with IgE-mediated conditions
|
|
DE10161767T1
(de)
|
2002-07-03 |
2018-06-07 |
Honjo Tasuku |
Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
|
|
AU2003259294A1
(en)
|
2002-07-30 |
2004-02-16 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
WO2004020462A1
(ja)
|
2002-08-27 |
2004-03-11 |
Fujii, Nobutaka |
Ｃｘｃｒ４拮抗薬およびその用途
|
|
JP4781621B2
(ja)
|
2002-08-27 |
2011-09-28 |
バイオカイン セラピューティックス リミテッド |
Ｃｘｃｒ４拮抗薬およびその用途
|
|
DE10240064A1
(de)
|
2002-08-30 |
2004-03-11 |
Universitätsklinikum Freiburg |
CXCR4-Rezeptor-Antagonisten
|
|
EP2806025B1
(en)
|
2002-09-05 |
2019-04-03 |
California Institute of Technology |
Use of zinc finger nucleases to stimulate gene targeting
|
|
EP1558648B1
(en)
|
2002-10-17 |
2012-01-11 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
EP1571146A4
(en)
|
2002-12-10 |
2010-09-01 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
|
|
JP2006514024A
(ja)
|
2002-12-23 |
2006-04-27 |
イネイト・ファーマ |
Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
|
|
EP1576014B1
(en)
|
2002-12-23 |
2011-06-29 |
Wyeth LLC |
Antibodies against pd-1 and uses thereof
|
|
US20050002939A1
(en)
|
2002-12-23 |
2005-01-06 |
Albert Zlotnik |
Tumor killing/tumor regression using CXCR4 antagonists
|
|
CA2520406A1
(en)
*
|
2003-03-27 |
2004-10-14 |
Emory University |
Cxcr4 antagonists and methods of their use
|
|
WO2004094409A1
(en)
|
2003-03-27 |
2004-11-04 |
Lankenau Institute For Medical Research |
Novel ido inhibitors and methods of use
|
|
WO2004091518A2
(en)
|
2003-04-11 |
2004-10-28 |
Anormed Inc. |
Cxcr4 chemokine receptor binding compounds
|
|
US8545463B2
(en)
|
2003-05-20 |
2013-10-01 |
Optimyst Systems Inc. |
Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
|
|
US7618632B2
(en)
|
2003-05-23 |
2009-11-17 |
Wyeth |
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
ES2393485T3
(es)
|
2003-07-02 |
2012-12-21 |
Innate Pharma |
Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
|
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
|
JP5642328B2
(ja)
|
2003-07-24 |
2014-12-17 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物
|
|
CA2541006C
(en)
|
2003-10-03 |
2015-02-17 |
Brigham And Women's Hospital |
Tim-3 polypeptides
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
WO2005037306A1
(en)
|
2003-10-17 |
2005-04-28 |
Novo Nordisk A/S |
Combination therapy
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
WO2005079766A2
(en)
|
2004-02-20 |
2005-09-01 |
Novo Nordisk A/S |
Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
|
|
WO2005089788A1
(ja)
|
2004-03-19 |
2005-09-29 |
Morinaga Milk Industry Co., Ltd. |
癌治療のための薬剤
|
|
WO2005105849A1
(en)
|
2004-04-30 |
2005-11-10 |
Innate Pharma |
Compositions and methods for treating proliferative disorders such as nk-type ldgl
|
|
US20060287229A1
(en)
|
2004-07-01 |
2006-12-21 |
Dani Eshel |
Novel CD40 variants
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
EP1773846A4
(en)
|
2004-07-13 |
2008-10-08 |
Univ British Columbia |
INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
|
|
US20060014264A1
(en)
|
2004-07-13 |
2006-01-19 |
Stowers Institute For Medical Research |
Cre/lox system with lox sites having an extended spacer region
|
|
CA2577046A1
(en)
|
2004-08-13 |
2006-02-23 |
Anormed Inc. |
Chemokine combinations to mobilize progenitor/stem cells
|
|
US20090104170A1
(en)
|
2004-11-02 |
2009-04-23 |
Richard William Wyatt Childs |
Compositions and methods for treating hyperproliferative disorders
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
US20080233053A1
(en)
|
2005-02-07 |
2008-09-25 |
Pharmalight Inc. |
Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
|
|
EP1850872A4
(en)
|
2005-02-15 |
2008-10-15 |
Gtc Biotherapeutics Inc |
METHOD FOR USE OF ANTI-CD-137 ANTIBODY AS RADIOIMMUN THERAPY OR RADIO IMMUNE DETECTION MEANS
|
|
EP1851244A4
(en)
|
2005-02-15 |
2009-04-15 |
Gtc Biotherapeutics Inc |
ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
|
|
WO2006105021A2
(en)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
|
SI2650020T1
(sl)
|
2005-05-06 |
2017-03-31 |
Providence Health & Services - Oregon Technology Transfer |
Trimerični OX40 imunoglobulinski fuzijski protein in postopek za njegovo uporabo
|
|
EP2161336B2
(en)
|
2005-05-09 |
2017-03-29 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
SG10201809390QA
(en)
|
2005-05-10 |
2018-11-29 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
|
EP1898943B1
(en)
|
2005-05-25 |
2012-10-10 |
Hadasit Medical Research Services & Development Ltd. |
Cxcr4 antagonists for wound healing and re-epithelialization
|
|
CA2612200A1
(en)
|
2005-06-15 |
2006-12-21 |
London Health Sciences Centre Research Inc. |
Method of cancer treatment using sirna silencing
|
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
WO2007022523A2
(en)
|
2005-08-19 |
2007-02-22 |
Genzyme Corporation |
Methods to enhance chemotherapy
|
|
CA2622629A1
(en)
|
2005-09-15 |
2007-03-29 |
Duke University |
Aptamers as agonists
|
|
US7705022B2
(en)
|
2005-10-27 |
2010-04-27 |
Lankenau Institute For Medical Research |
IDO inhibitors and methods of use thereof
|
|
EP1974018A4
(en)
|
2005-12-08 |
2010-01-27 |
Univ Louisville Res Found |
VSEL (VERY SMALL EMBRYONIC LIKE) STEM CELLS AND METHOD OF ISOLATING AND USE THEREOF
|
|
EP1971583B1
(en)
|
2005-12-20 |
2015-03-25 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
WO2007120368A2
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
|
EP2889309B1
(en)
|
2006-03-03 |
2017-12-27 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of pd-1 or pd-l1
|
|
EP2032691A2
(en)
|
2006-06-15 |
2009-03-11 |
Neostem, Inc |
Processing procedure for peripheral blood stem cells
|
|
WO2008017025A2
(en)
|
2006-08-02 |
2008-02-07 |
Genzyme Corporation |
Combination therapy
|
|
JP5065273B2
(ja)
|
2006-08-04 |
2012-10-31 |
学校法人 久留米大学 |
Ｈｌａ−ａ２４分子結合性ｋｉｆ由来ペプチド
|
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
US20100061992A1
(en)
|
2006-11-15 |
2010-03-11 |
The Brigham And Women's Hospital, Inc. |
Therapeutic uses of tim-3 modulators
|
|
GB0624308D0
(en)
|
2006-12-05 |
2007-01-17 |
Molmed Spa |
Combination product
|
|
US20100184694A1
(en)
|
2006-12-21 |
2010-07-22 |
Biokine Therapeutics Ltd. |
T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
|
|
CN101578113B
(zh)
|
2007-01-11 |
2015-04-22 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
EP2137168B1
(en)
|
2007-03-16 |
2016-09-14 |
Lankenau Institute for Medical Research |
Novel ido inhibitors and methods of use thereof
|
|
AU2008247382B2
(en)
|
2007-05-07 |
2014-06-05 |
Medimmune, Llc |
Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
AU2008266951C1
(en)
|
2007-06-18 |
2025-06-19 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor PD-1
|
|
WO2009009116A2
(en)
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
|
GB0722274D0
(en)
|
2007-11-13 |
2007-12-27 |
Ludwig Inst Cancer Res |
New therapeutic method
|
|
WO2009073620A2
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics |
Ido inhibitors
|
|
EP2067402A1
(en)
|
2007-12-07 |
2009-06-10 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Transponson-mediated mutagenesis in spermatogonial stem cells
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2009126804A2
(en)
|
2008-04-11 |
2009-10-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
|
|
JP2011518841A
(ja)
|
2008-04-24 |
2011-06-30 |
ニューリンク ジェネティクス， インコーポレイテッド |
Ｉｄｏ阻害剤
|
|
US9931386B2
(en)
|
2008-06-16 |
2018-04-03 |
Atsuo Ochi |
Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
|
|
RS57132B1
(sr)
|
2008-07-08 |
2018-07-31 |
Incyte Holdings Corp |
1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
|
|
US20110257256A1
(en)
|
2008-07-31 |
2011-10-20 |
Bionoria Research Gmbh |
Cannabinoids for use in treating or preventing cognitive impairment and dementia
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
WO2010027827A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
JP2012501323A
(ja)
|
2008-08-29 |
2012-01-19 |
アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク |
対象の腫瘍流入領域リンパ節へのｃｄ４０アゴニストの送達
|
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
ES2592216T3
(es)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
|
|
SI2370593T1
(sl)
|
2008-11-28 |
2016-08-31 |
Emory University |
Postopek za določanje učinkovitosti antagonista pd-1
|
|
KR20190069615A
(ko)
|
2008-12-09 |
2019-06-19 |
제넨테크, 인크. |
항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
WO2010105068A1
(en)
|
2009-03-13 |
2010-09-16 |
The Trustees Of The University Of Pennsylvania |
Ox40/trail fusion proteins
|
|
WO2010111172A1
(en)
|
2009-03-23 |
2010-09-30 |
Ambit Biosciences Corporation |
Methods of treatment using combination therapy
|
|
WO2010117057A1
(ja)
|
2009-04-10 |
2010-10-14 |
協和発酵キリン株式会社 |
抗tim-3抗体を用いた血液腫瘍治療法
|
|
EP2243833A1
(en)
|
2009-04-22 |
2010-10-27 |
Erasmus University Medical Center Rotterdam |
Method for the treatment of acute myeloid leukemia
|
|
ES2462517T3
(es)
|
2009-06-14 |
2014-05-23 |
Biokine Therapeutics Ltd. |
Terapia con péptidos para aumentar los niveles de plaquetas
|
|
BRPI1009716A2
(pt)
|
2009-06-15 |
2016-10-11 |
Biokine Therapeutics Ltd |
ligações péptidicas de quemoquina, capazes de inibir o curso da autoimunidade, inflamação e câncer
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
CN102574924A
(zh)
|
2009-09-03 |
2012-07-11 |
先灵公司 |
抗-gitr抗体
|
|
CN102740887B
(zh)
|
2009-09-30 |
2015-04-15 |
斯隆凯特林防癌纪念中心 |
用于治疗癌症的组合免疫疗法
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
WO2011069121A1
(en)
|
2009-12-04 |
2011-06-09 |
Neostem, Inc. |
Mesenchymal stem cells (mscs) isolated from mobilized peripheral blood
|
|
CN102918059A
(zh)
|
2009-12-29 |
2013-02-06 |
协和发酵麒麟株式会社 |
抗cd27抗体
|
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
|
EP2533779A4
(en)
|
2010-02-09 |
2013-08-21 |
Georgia Health Sciences University Res Inst Inc |
ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE
|
|
DK2542590T4
(da)
|
2010-03-05 |
2020-07-13 |
Univ Johns Hopkins |
Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
ES2682078T3
(es)
|
2010-06-11 |
2018-09-18 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-TIM-3
|
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
SG10201506906VA
(en)
|
2010-09-09 |
2015-10-29 |
Pfizer |
4-1bb binding molecules
|
|
US20120082687A1
(en)
|
2010-10-04 |
2012-04-05 |
Alex Wah Hin Yeung |
Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
|
|
US20130303460A1
(en)
|
2011-01-10 |
2013-11-14 |
Biokine Therapeutics Ltd. |
Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
|
|
CA2826582A1
(en)
|
2011-02-10 |
2012-08-16 |
University Of Louisville Research Foundation, Inc. |
Adjuvant compositions with 4-1bbl
|
|
KR101905113B1
(ko)
|
2011-03-31 |
2018-10-10 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Icos에 대한 항체 및 이의 용도
|
|
NO2694640T3
(show.php)
|
2011-04-15 |
2018-03-17 |
|
|
|
CA2834404C
(en)
|
2011-04-29 |
2020-02-11 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
CA2837184C
(en)
|
2011-05-25 |
2021-09-21 |
Innate Pharma, S.A. |
Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
|
|
US20140234320A1
(en)
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
TR201820873T4
(tr)
|
2011-08-01 |
2019-01-21 |
Hoffmann La Roche |
Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
HUE043001T2
(hu)
|
2011-11-09 |
2019-07-29 |
Bristol Myers Squibb Co |
Hematológiai malignómák kezelése anti-CXCR4 antitesttel
|
|
CN103170757A
(zh)
*
|
2011-12-23 |
2013-06-26 |
富泰华工业（深圳）有限公司 |
锡膏及其制备方法
|
|
AU2013225619A1
(en)
|
2012-02-29 |
2014-10-16 |
Benitec Biopharma Limited |
Pain treatment
|
|
EP2822957A1
(en)
|
2012-03-07 |
2015-01-14 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
WO2013160895A1
(en)
|
2012-04-24 |
2013-10-31 |
Biokine Therapeutics Ltd. |
Peptides and use thereof in the treatment of large cell lung cancer
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
EP2879709B1
(en)
|
2012-07-31 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Modulation of the immune response
|
|
CA2889182A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
CN110066335B
(zh)
|
2012-10-30 |
2024-04-05 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
US20140147411A1
(en)
|
2012-11-14 |
2014-05-29 |
U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS |
Methods of treating cancer and testing mutation zygosity related thereto
|
|
US9073875B2
(en)
|
2012-11-20 |
2015-07-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
|
PT3502240T
(pt)
|
2012-11-27 |
2021-08-11 |
Childrens Medical Ct Corp |
Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal
|
|
PT2925350T
(pt)
|
2012-12-03 |
2019-03-25 |
Bristol Myers Squibb Co |
Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
|
|
KR101671291B1
(ko)
|
2012-12-05 |
2016-11-01 |
더백스 제네틱스 백신 코포레이션, 엘티디. |
항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP2943571A4
(en)
|
2013-01-08 |
2016-11-30 |
Benitec Biopharma Ltd |
TREATMENT OF AGE-RELATED MACULAR GENERATION
|
|
WO2014121099A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Agonist fusion protein for cd40 ox40 and uses thereof
|
|
DK2970473T3
(da)
|
2013-03-14 |
2017-11-27 |
Bristol Myers Squibb Co |
Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
|
|
SG10201802982WA
(en)
|
2013-03-14 |
2018-06-28 |
Icahn School Med Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
EP3404116B1
(en)
|
2013-03-15 |
2022-10-19 |
The University of Chicago |
Methods and compositions related to t-cell activity
|
|
KR101763352B1
(ko)
|
2013-03-15 |
2017-07-31 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
항ｌａｇ3 결합 단백질
|
|
MX2015012056A
(es)
|
2013-03-15 |
2015-12-16 |
Squibb Bristol Myers Co |
Inhibidores de indolamina-2,3-dioxigenasa (ido).
|
|
SI2970155T1
(en)
|
2013-03-15 |
2018-06-29 |
Bristol-Myers Squibb Company |
INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO)
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
WO2014155376A1
(en)
|
2013-03-24 |
2014-10-02 |
Biokine Therapeutics Ltd. |
Methods of treating myeloid leukemia
|
|
JP2016531907A
(ja)
|
2013-08-02 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． |
免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
|
|
EP3030322A2
(en)
*
|
2013-08-05 |
2016-06-15 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3062809B1
(en)
|
2013-10-31 |
2020-07-08 |
Biokine Therapeutics Ltd. |
A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
|
|
IL292510A
(en)
*
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
US20180161366A1
(en)
|
2015-05-20 |
2018-06-14 |
Biokine Therapeutics Ltd. |
Methods of obtaining mononuclear blood cells and uses thereof
|
|
CN116196426A
(zh)
|
2015-07-16 |
2023-06-02 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
CA3014530A1
(en)
|
2016-02-23 |
2017-08-31 |
Biolinerx Ltd. |
Methods of treating acute myeloid leukemia
|
|
CN113164600A
(zh)
|
2018-10-17 |
2021-07-23 |
百欧林纳克斯有限公司 |
转移性胰脏腺癌的治疗
|